CALCA and migraine disorder: While the role of CGRP with its vasodilation potency has long been confirmed by effective migraine therapies using CGRP receptor antagonists [106–108] or monoclonal antibodies targeting CGRP or its receptors [109–111], therapies targeting SP or its main effect, i.e. plasma extravasation, have failed [112].